Enliven Therapeutics

Update in progress

ELVN (NasdaqGS)

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule inhibitors for cancer. Its programs include ELVN-001, a kinase inhibitor in Phase 1 for adults with chronic myeloid leukemia, and ELVN-002, a CNS-penetrant, irreversible HER2 inhibitor in Phase 1 for NSCLC and other HER2-mutant tumors. Founded in 2019, it is based in Boulder, Colorado.